Chronic Heart Failure and Lipidology
We recommend
Inclisiran − a new addition to the arsenal of dyslipidemia treatment
At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in Prague, lectures on innovative dyslipidemia therapy using the small interfering RNA molecule − inclisiran were presented at the Novartis company symposium.
Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention
Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk…
Practical Experiences Using ZULP in Cardiology
The application of a product containing ferric carboxymaltose (FCM) or the use of a contrast agent…
Articles on this topic
1
2
Subscribe
Most read on this topic
Related topic
Interesting links
Most read on this topic
- INFOGRAPHIC: LDL Cholesterol - Recommended Target Values
- Inclisiran − a new addition to the arsenal of dyslipidemia treatment
- Pharmacotherapy of Chronic Heart Failure with Reduced EF LV - Latest ESC Recommendations
- The heart transplantation
- Practical Experiences Using ZULP in Cardiology
- How to Achieve Left Ventricular Reverse Remodeling and Improve Outcomes in Heart Failure? Summary from HFA ESC Webinar
Related topic
Interesting links